Eloralintide is Lilly's once-weekly selective amylin receptor agonist, tested alone and paired with tirzepatide as "EloraTZP". Neither is approved. On its own, eloralintide produced up to 20.1% weight loss at 48 weeks in Phase 2. EloraTZP produced up to 23.3% at 48 weeks in people with type 2 diabetes, against 14.8% for tirzepatide 15 mg in the same trial. Retatrutide produced 20.8% at 80 weeks in its type 2 diabetes trial. Those numbers come from different trials, populations and durations, and no trial has compared EloraTZP with retatrutide directly.
No trial has put EloraTZP and retatrutide in the same study. The numbers circulating on Reddit compare a 32-week Phase 1 arm with an 80-week Phase 3 result, across different populations. Line the trials up by population and duration and EloraTZP looks competitive with retatrutide in type 2 diabetes, on less evidence and with more people stopping for side effects.
What is eloralintide?
Eloralintide is an investigational once-weekly injectable from Eli Lilly, previously coded LY3841136. Lilly describes it as a selective amylin receptor agonist whose effect "is likely mediated by affecting satiety." The 30 September 2026 EloraTZP release adds that it has "minimal activity at the calcitonin receptor," which is the main design difference from Novo Nordisk's cagrilintide.
Its Phase 2 trial (NCT06230523) randomized 263 adults with obesity or overweight and no diabetes. At 48 weeks, by the efficacy estimand, weight fell 9.5% on 1 mg, 12.4% on 3 mg, 17.6% on 6 mg and 20.1% on 9 mg, against 0.4% on placebo, according to Lilly's 6 November 2025 release. The results were presented at ObesityWeek 2025 and published in The Lancet the same day. Lilly said it would begin Phase 3 enrollment by the end of 2025, and its September 2026 releases describe Phase 3 trials of eloralintide alone as ongoing.
EloraTZP is eloralintide combined with tirzepatide. In the Phase 2b trial (NCT06603571), participants took the two as separate injections. Lilly plans to start Phase 3 of a single co-formulated product by the end of 2026.
"Retatrutide is being dethroned by eloraTZP": what does the data say?
The claim comes from a 30 September r/Retatrutide post with 489 upvotes and 355 comments, posted the day both trials were presented at EASD in Milan. It set out two comparisons:
- Obesity without diabetes: "eloraTZP 29% weight loss at 32 weeks" against "retatrutide 28.3% weight loss at 80 weeks."
- Obesity with type 2 diabetes: "eloraTZP 23.3% weight loss at 48 weeks" against "retatrutide 20.8% weight loss at 80 weeks."
The second comparison holds up as stated. Both figures are real, both use the efficacy estimand, and both come from people with type 2 diabetes. Even so, the trial populations differ: EloraTZP participants started at a mean HbA1c of 8.1% and 105.4 kg, while TRIUMPH-2 participants started at 7.71% and a mean BMI of 38.2. TRIUMPH-2 is also published in The Lancet; the EloraTZP Phase 2b result so far exists as a conference presentation and company release.
The first comparison does not hold up. Lilly's 15 September release reported only the Phase 1 headline that eloralintide 3 mg added to tirzepatide 5 mg produced 17% loss over 16 weeks, against 10% for tirzepatide 5 mg alone. The 29% figure appears in coverage of the Phase 1 abstract (On The Pen, 30 September 2026) as a week-31 result for the high-dose combination, against about 17.8% for tirzepatide 15 mg. One analyst, Clinaptis Research (30 September 2026), reported that this arm had 3 of 12 participants with an end-of-treatment value. We have not read the abstract and cannot confirm the completer count. Either way, a Phase 1 arm of about a dozen people is not comparable with TRIUMPH-1's 2,339.
The thread's own top comments split between excitement and doubt. "Faster weight loss does not make it a better drug," one reply read. Another: "Side effect profile matters more than loss percentages to me."
Eloralintide vs retatrutide: trial results side by side
| Program | Trial | Phase | Population | n | Weeks | Estimand | Top-dose mean loss | Placebo |
|---|---|---|---|---|---|---|---|---|
| Eloralintide alone | NCT06230523 | 2 | obesity, no diabetes | 263 | 48 | efficacy | −20.1% (9 mg) | −0.4% |
| Eloralintide alone | NCT06603571 | 2b | obesity + type 2 diabetes | 367 (whole trial) | 48 | efficacy | −12.3% (6 mg) | −3.0% |
| EloraTZP | NCT06603571 | 2b | obesity + type 2 diabetes | 367 (whole trial) | 48 | efficacy | −23.3% (9 mg + 15 mg) | −3.0% |
| Tirzepatide alone | NCT06603571 | 2b | obesity + type 2 diabetes | 367 (whole trial) | 48 | efficacy | −14.8% (15 mg) | −3.0% |
| EloraTZP | Phase 1 | 1 | overweight or obesity | about 12–16 per arm | 16 | efficacy | −17% (3 mg + 5 mg) | tirzepatide 5 mg −10% |
| Retatrutide | Phase 2, NEJM 2023 | 2 | obesity, no diabetes | 338 | 48 | least-squares mean | −24.2% (12 mg) | −2.1% |
| Retatrutide | TRIUMPH-1 | 3 | obesity, no diabetes | 2,339 | 80 | efficacy | −28.3% (12 mg) | see TRIUMPH page |
| Retatrutide | TRIUMPH-2 | 3 | obesity + type 2 diabetes | 1,152 | 80 | efficacy / treatment-regimen | −20.8% / −18.8% (12 mg) | −4.0% / −5.1% |
Sources by row: Lilly 6 November 2025; Lilly 30 September 2026 (rows two to four); Lilly 15 September 2026; NEJM 2023; Lilly 21 May 2026; The Lancet, 29 September 2026 and Lilly 29 September 2026.
Three points come out of the table.
At 48 weeks without diabetes, retatrutide alone still leads eloralintide alone: 24.2% on 12 mg in its Phase 2 against 20.1% on 9 mg, from two separate trials with slightly different analyses. No EloraTZP result in people without diabetes exists beyond Phase 1.
In type 2 diabetes, EloraTZP's top dose matches or beats retatrutide's headline in 32 fewer weeks. Both use the efficacy estimand, which assumes everyone stayed on drug. On blood sugar, EloraTZP cut HbA1c by up to 2.9 points from 8.1%. Retatrutide cut it by 1.4 to 1.6 points from 7.71%, with no dose response, according to Fierce Biotech (30 September 2026). A higher starting HbA1c leaves more room to fall.
Tolerability looks worse for the combination so far. Lilly reported that 10.8% to 27.0% of EloraTZP participants stopped treatment for adverse events, against 2.9% on tirzepatide alone and, oddly, 16.7% on placebo. In TRIUMPH-2, discontinuation for adverse events or death ran 4%, 12% and 8% on 4, 9 and 12 mg retatrutide, against 5% on placebo. The EloraTZP arms had about 37 people each, so one or two dropouts move those percentages by several points.
Responder rates follow the same split. On EloraTZP 9 mg + 15 mg, 63% lost at least 20% at 48 weeks and 25% lost at least 30%, according to Healio (2 October 2026). On retatrutide 12 mg in TRIUMPH-2, 52.0% lost at least 20% at 80 weeks by Lilly's figures.
How do amylin agonists differ from GLP-1, GIP and glucagon agonists?
Retatrutide is one molecule that activates three receptors: GIP, GLP-1 and glucagon. Eloralintide works on a different system. Amylin is released with insulin by the pancreas after meals and signals fullness through the brainstem. Lilly's Rachel Batterham put the distinction this way to Healio: "amylin works through a completely different mechanism of action." That is the rationale for stacking it on tirzepatide rather than replacing tirzepatide.
The first amylin analog, pramlintide, needed injections at every meal. Eloralintide and cagrilintide are long-acting versions given weekly. Our cagrilintide guide covers Novo Nordisk's compound, which also acts on calcitonin receptors. For how retatrutide's three-receptor design compares with tirzepatide's two, see retatrutide vs tirzepatide and the retatrutide guide.
Is eloralintide sold as a research peptide yet?
Yes. When we searched on 5 October 2026, we found eloralintide on at least eight gray-market storefronts, in 5 mg and 10 mg vials, two of them as pre-orders and some under the short name "Elora". Several listings cite Janoshik reports, the earliest dated late July 2026, and two say their current lot measured roughly 24% to 25% above the 10 mg label. One cites a Czech lab instead. Reddit commenters in the 30 September threads already describe combining "Elora" with retatrutide. No trial we read has tested that combination.
What our data shows: zero eloralintide records in our Janoshik mirror (337 public reports, through 30 June 2026) or our Kovera mirror (1,828 certificates, snapshot 1 August 2026, latest test 16 July). The vendor-cited Janoshik reports postdate our Janoshik snapshot, and Janoshik's public listing blocked our automated check for this piece, so we have not resolved them. Until we do, treat every eloralintide certificate as a vendor claim.
Two checks matter more than usual for a compound this new:
- Identity by mass spectrometry. A lab can compare the main peak's mass with the published eloralintide structure. Ask whether the report confirms identity by LC-MS or only gives HPLC purity. A purity number on its own says nothing about what the peptide is.
- How content was quantified. Ask what reference standard the lab measured content against. For a compound that entered the gray market in mid-2026, that answer is not a formality.
Then resolve the report number on the lab's own site with our COA verifier and match the lot on the vial. Coded names are the next step in this market: retatrutide already sells as "GLP-3 RT", and FDA quoted those code names back to vendors in its August 2026 letters. Our code-name catalogs report tracks the pattern.
Where do CagriSema, survodutide and mazdutide fit?
| Drug | Mechanism | Trial | Weeks | Estimand | Result | Status |
|---|---|---|---|---|---|---|
| CagriSema (Novo Nordisk) | amylin/calcitonin + GLP-1, two molecules | REDEFINE 1, NEJM 2025 | 68 | treatment-policy | −20.4% vs −3.0% | US decision guided to Q4 2026 |
| Survodutide (Boehringer Ingelheim) | glucagon + GLP-1 | SYNCHRONIZE-1, NEJM 2026 | 76 | treatment-regimen | −12.2% (3.6 mg), −13.0% (6.0 mg) vs −5.4% | Phase 3 |
| Mazdutide (Innovent) | glucagon + GLP-1 | GLORY-1, China, NEJM 2025 | 48 | treatment-policy | −11.00% (4 mg), −14.01% (6 mg) vs +0.30% | studied in China |
CagriSema is the closest analog to EloraTZP: an amylin analog on top of an incretin, in two molecules. On 21 September 2026 Novo reported that CagriSema 1.0/1.0 mg beat tirzepatide 5 mg in type 2 diabetes, 12.4% vs 9.1% at week 60. That comparison used low doses and does not show CagriSema beating tirzepatide 15 mg.
Survodutide and mazdutide sit in a different class, glucagon plus GLP-1, and both trail the triple and amylin combinations on weight. FDA's 24 August 2026 warning letter to NuScience Peptides named both among the products the vendor sold.
What we read
- Lilly releases of 6 November 2025 (eloralintide Phase 2), 15 September 2026 (EASD preview with the Phase 1 headline), 29 September 2026 (TRIUMPH-2) and 30 September 2026 (EloraTZP Phase 2b).
- The TRIUMPH-2 abstract in The Lancet and the retatrutide, CagriSema, survodutide and mazdutide papers in NEJM.
- Conference coverage from Healio, Medscape, HCPLive, Fierce Biotech and On The Pen, and one analyst note from Clinaptis Research.
- Two Reddit threads from 30 September 2026: the r/Retatrutide "dethroned" post (489 upvotes, 355 comments) and the r/Biohackers "Phase 1B" post (73 upvotes, 80 comments).
- Our Janoshik and Kovera mirrors, searched for eloralintide, LY3841136 and "Elora".
- Gray-market product pages listing eloralintide, read on 5 October 2026.
What we did not read
The EloraTZP Phase 1 abstract itself, the full eloralintide Phase 2 paper in The Lancet, and any EloraTZP journal publication, which did not exist at the time of writing. We did not resolve vendor-cited eloralintide certificates on the issuing labs' sites, and we did not test any eloralintide vial.
Sources
- Lilly, eloralintide Phase 2 results, 6 November 2025
- Lilly, EASD 2026 preview with EloraTZP Phase 1 headline, 15 September 2026
- Lilly, EloraTZP Phase 2b results, 30 September 2026
- Lilly, TRIUMPH-2 detailed results, 29 September 2026
- Lilly, TRIUMPH-1 results, 21 May 2026
- TRIUMPH-2, The Lancet, 29 September 2026
- Retatrutide Phase 2, NEJM, 2023
- CagriSema REDEFINE 1, NEJM, 2025
- Survodutide SYNCHRONIZE-1, NEJM, 7 June 2026
- Mazdutide GLORY-1, NEJM, 25 May 2025
- Novo Nordisk, REIMAGINE 5 release, 21 September 2026
- Healio, combining eloralintide with tirzepatide, 2 October 2026
- Fierce Biotech, full Phase 3 retatrutide data, 30 September 2026
- On The Pen, tirzepatide-eloralintide Phase 1 coverage, 30 September 2026
- Clinaptis Research, eloralintide + tirzepatide preview, 30 September 2026
- r/Retatrutide, Retatrutide is being dethroned by eloraTZP, 30 September 2026
- r/Biohackers, Phase 1B study shows eloralintide + tirzepatide obliterate retatrutide, 30 September 2026
- Internal: TRIUMPH results, retatrutide vs tirzepatide, cagrilintide, retatrutide
Frequently asked
What is eloralintide?
Eloralintide, formerly LY3841136, is an investigational once-weekly injectable from Eli Lilly that activates amylin receptors with minimal calcitonin receptor activity. Amylin is a hormone released with insulin after meals that signals fullness. Eloralintide is in Phase 3 trials on its own and is not approved anywhere.
What is EloraTZP?
EloraTZP is Lilly's name for eloralintide combined with tirzepatide, the GIP and GLP-1 agonist in Zepbound and Mounjaro. In the Phase 2b trial the two drugs were given as separate injections. Lilly says it will start Phase 3 trials of a single co-formulated product by the end of 2026.
Is retatrutide being dethroned by eloraTZP?
Not on current evidence. The 490-upvote Reddit claim compares a 29% result from a tiny Phase 1 arm at 32 weeks with retatrutide's 28.3% from a 2,339-person Phase 3 trial at 80 weeks. The fairer comparison, both in type 2 diabetes, is 23.3% at 48 weeks for EloraTZP against 20.8% at 80 weeks for retatrutide, from separate trials.
Does eloralintide plus tirzepatide obliterate retatrutide?
The Phase 1 headline behind that claim exists, but it rests on cohorts of roughly 12 to 16 people per arm. Lilly's own release for the 367-person Phase 2b trial does not compare EloraTZP with retatrutide at all, and discontinuation for side effects ran 10.8% to 27.0% on the combination.
Can you buy eloralintide as a research peptide?
Several gray-market storefronts listed eloralintide when we searched on 5 October 2026, citing certificates dated from late July 2026. Our mirrors of Janoshik and Kovera certificates, which end in July 2026, contain no eloralintide records, so we cannot yet verify any vendor's claim from lab-side data.
Is eloralintide the same as cagrilintide?
No. Both are long-acting amylin analogs, but cagrilintide, from Novo Nordisk, acts on both amylin and calcitonin receptors and is paired with semaglutide in CagriSema. Lilly describes eloralintide as selective for the amylin receptor, with minimal calcitonin receptor activity.